Skip to content
lifestyle.chroniccities.us
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
Vascarta Inc
Vascarta Announces Phase I Results of VAS-101 Administered Sublingually in Sickle Cell Disease Patients
June 24, 2026
Vascarta Announces Positive Clinical Trial Results for Topical/Transdermal Curcumin Gel VAS-101 in Knee Osteoarthritis
April 1, 2026
Novel Transdermal Curcumin (VAS-101) Improves Cardiac Mitochondrial Function in Sickle Cell Disease Mouse Model, New FDA Led Study Shows
December 4, 2025